指南与共识银屑病与炎症性皮肤病

确定用于临床试验中评估银屑病的核心领域集

Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials.
指南 / 共识 · JAMA Dermatol · 2018-01-01

通过文献回顾、德尔菲调查和利益相关者会议,在国际范围内就所有银屑病临床试验应测量的核心领域达成共识。两轮德尔菲调查后,从20个候选领域中确定6个核心领域:皮肤表现、银屑病及银屑病关节炎症状、健康相关生活质量、研究者整体评估、患者整体评估和治疗满意度。

要点

  • 6个核心领域应在所有银屑病临床试验中测量。
  • 次要皮肤表现及甲、反向、生殖器和点滴状银屑病重要但非必需。
  • 银屑病关节炎体征、工作生产力、经济影响和心血管疾病列入研究议程。

核心结论

  • 迭代德尔菲过程在专业和患者利益相关者间达成国际共识,确定6个应在所有银屑病临床试验中测量的领域。

研究设计与样本

  • 文献回顾、德尔菲前调查、名义小组讨论和4次利益相关者会议投票,用于开发候选领域并进行两轮德尔菲调查。
  • 德尔菲调查于2015年10月至12月及2016年9月至10月电子进行;利益相关者讨论与投票于2013年1月至2016年12月在美国、加拿大和意大利的现场会议进行。
  • 第一轮德尔菲调查有107名卫生保健专业人员和14名患者参与;第二轮有77名卫生保健专业人员和15名患者参与。

主要发现

  • 第一轮中大多数卫生保健专业人员为皮肤科医生(72/107,67%),46至64岁(71/107,66%),白人(78/107,73%),男性(75/107,70%),来自北美(60/107,57%)和欧洲(34/107,32%)。
  • 20个候选领域中有6个达到核心领域共识:皮肤表现、银屑病及银屑病关节炎症状、健康相关生活质量、研究者整体评估、患者整体评估和治疗满意度。
  • 次要皮肤表现以及甲、反向、生殖器和点滴状银屑病被归类为重要但非强制测量。
  • 银屑病关节炎体征、工作生产力或参与、经济影响(直接和间接成本)和心血管疾病组成研究议程。

关键数值与推荐

  • 若在患者和卫生保健专业人员两组中均达到至少70%的共识阈值,则该领域被视为「核心」(即在所有试验中应测量)。
  • 仅在1组中达到共识的领域被视为重要但不要求在所有试验中测量(「中间环」),纳入第二轮重新评级。
  • 在两组中均未达到共识的领域(「外环」)被视为重要性不确定,列入研究议程。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There is no consensus on which domains should be measured or which instruments should be used in clinical trials for psoriasis therapies. OBJECTIVE: To achieve international consensus among psoriasis stakeholders on a core set of domains that should be measured in all psoriasis clinical trials. DESIGN, SETTING, AND PARTICIPANTS: Literature review, pre-Delphi survey exercises, nominal group discussions, and audience voting at 4 stakeholder meetings were used to develop candidate domains for 2 rounds of a Delphi survey. Stakeholders were patients or advocates of patients with psoriasis and health care professionals (HCPs) with expertise in psoriasis, including physicians, scientists, advocacy organization representatives, and regulators. Delphi surveys were conducted electronically from October through December 2015 and between September and October 2016. Stakeholder discussions with audience response voting were conducted at live meetings in the United States, Canada, and Italy from January 2013 to December 2016 to refine and ratify the core set of domains. MAIN OUTCOMES AND MEASURES: Two rounds of an electronic Delphi survey were used to determine consensus. A domain was considered "core" (ie, should be measured in all trials) if a threshold consensus of at least 70% was met in both patient and HCP groups. Domains meeting consensus in only 1 group were considered to be important but were not required to be measured in all trials ("middle ring"). These domains were included for rerating in round 2. Domains that did not meet consensus in either of the groups ("outer ring") were considered to be of uncertain importance and were placed in the research agenda. RESULTS: In round 1 of the Delphi survey, 107 HCPs and 14 patients participated. Most HCPs (72 [67%]) were dermatologists between 46 and 64 years old (71 [66%]), white (78 [73%]), and male (75 [70%]) from North America (60 [57%]) and Europe (34 [32%]).There were 10 pharmaceutical industry clinical or health economic scientists, 3 advocacy organization representatives, 2 regulatory agency representatives, and 5 "other." In the second round, 77 HCPs and 15 patients participated. Of the 20 candidate domains, the following 6 met consensus as core domains: skin manifestations, psoriasis and psoriatic arthritis symptoms, health-related quality of life, investigator global assessment, patient global assessment, and treatment satisfaction. Secondary skin manifestations as well as nail, inverse, genital, and guttate psoriasis were classified as important but not mandatory. Psoriatic arthritis signs, work productivity or participation, economic impact (direct and indirect cost), and cardiovascular disease comprised the research agenda. CONCLUSIONS AND RELEVANCE: This iterative Delphi process yielded international consensus among professional and patient stakeholders on 6 domains that should be measured in all clinical trials for psoriasis. Future International Dermatology Outcome Measures group efforts will focus on development of a core outcome measurement set for psoriasis trials.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Callis Duffin K, Merola JF, Christensen R, et al. Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials. JAMA Dermatol. 2018. PMID: 29874367. doi:10.1001/jamadermatol.2018.1165

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。